Amphista Enters Protein Degradation Collaborations with Bristol-Myers Squibb and Merck

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 5 (Table of Contents)

Published: 26 May-2022

DOI: 10.3833/pdr.v2022.i5.2691     ISSN: 1756-7874

Section: Research & Development



Amphista Therapeutics, a biotech focused on the discovery and development of next generation protein degradation therapeutics, has entered into two significant partnerships with pharma giants, Bristol Myers Squibb (BMS) and Merck KGaA...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details